Category:
Carcinomas
Cancer type:
Prostate
Descriptor:
HGF/SF expression
Reference Number:
1
Joseph, A. et al. Expression of scatter factor in human bladder carcinoma.
J Natl Cancer Inst 87, 372-7. (1995).
PubMed link
Reference Number:
119
Zhu, X. & Humphrey, P. A. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma.
Urology 56, 1071-4 (2000).
PubMed link
Reference Number:
248
Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue.
Oncol Rep 10:1149-53 (2003).
PubMed link
Reference Number:
325
MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL, Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
Prostate 64,139-48 (2005)
PubMed link
Reference Number:
326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor.
Oncogene 24, 101-6 (2005)
PubMed link
Reference Number:
363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Int J Oncol. 27, 1061-70 (2005)
PubMed link
Reference Number:
371
Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
Prostate 66, 447-52 (2006)
PubMed link
Reference Number:
372
Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases.
Oncogene. 25, 2367-78 (2006)
PubMed link
Reference Number:
373
Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil
Cytoskeleton 62, 180-94 (2005)
PubMed link
Reference Number:
376
Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG. Hepatocyte growth factor/scatter factor and prostate cancer: a review.
Histol Histopathol. 20, 1339-49 (2005)
PubMed link
Reference Number:
377
Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Eur Urol. 48, 686-90 (2005)
PubMed link
Reference Number:
378
Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.
Am J Pathol. 167, 255-66 (2005)
PubMed link
Reference Number:
379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Biochem J. 390, 125-36 (2005)
PubMed link
Reference Number:
380
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
FEBS Lett. 579, 1945-50 (2005)
PubMed link
Reference Number:
381
Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection.
Oncogene 24, 1749-66 (2005)
PubMed link
Reference Number:
382
MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
Prostate. 64, 139-48 (2005)
PubMed link
Reference Number:
385
Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms.
Cancer Res. 66, 794-802 (2006)
PubMed link
Reference Number:
386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer.
J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link
Reference Number:
396
Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering.
Cell Motil Cytoskeleton. 62, 180-94 (2005)
PubMed link
Reference Number:
475
Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
Clin Genitourin Cancer. 4, 269-74 (2006)
PubMed link
Reference Number:
587
Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
Prostate Cancer Prostatic Dis. 11, 258-63 (2008)
PubMed link
Reference Number:
588
Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro.
Int J Mol Med.
20, 613-9 (2007)
PubMed link
Reference Number:
621
Ye L, Lewis-Russell JM, Sanders AJ, Kynaston H, Jiang WG. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.
Urol Oncol.
26, 190-7 (2008)
PubMed link
Reference Number:
631
Shukla CJ, Pennington CJ, Riddick AC, Sethia KK, Ball RY, Edwards DR. Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions.
BJU Int.
101, 765-74 (2008)
PubMed link
Reference Number:
654
Ye L, Lewis-Russell JM, Sanders AJ, Kynaston H, Jiang WG. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.
Urol Oncol.
26, 190-7 (2008)
PubMed link
Reference Number:
687
Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A, Saiki I, Fuse H. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Prostate.
69, 346-51 (2009)
PubMed link
Reference Number:
688
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Clin Cancer Res.
14, 7385-90 (2008)
PubMed link
Reference Number:
720
Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A, Saiki I, Fuse H. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Prostate 69, 346-51 (2009)
PubMed link
